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ABSTRACT
Background: Toxoplasma gondii is an intracellular protozoan parasite that can cause a wide range of
clinical conditions, including miscarriage and pneumonia. The global prevalence is 30% in humans, but
varies by locality (e.g. in the UK it is typically 10%). The association between lung cancer and T. gondii
infection was investigated by direct detection in lung tissue samples.
Methods: Lung tissue samples were taken from patients undergoing lung resection surgery (n=72) for
suspected lung cancer (infection prevalence 100% (95% CI: 93.9–100%)). All 72 participants were
confirmed as having lung cancer following subsequent diagnostic tests. In addition, bronchial biopsy
samples were collected from non-lung cancer healthy control subjects (n=10). Samples were tested for
T. gondii using PCR amplification of T. gondii specific gene markers and T. gondii specific
immunohistochemistry.
Results: All 72 lung cancer patients were infected with T. gondii (prevalence 100% (95% CI: 93.9–100%)).
Of which, 95.8% (n=69) of patients showed evidence of active parasite stages. Infection prevalence in the
controls (10%) was significantly lower (p<0.0001).
Conclusions: Clinicians treating lung cancer patients should be aware of the potential presence of the
parasite, the potential for induction of symptomatic complications and interference with treatment success.
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ORIGINAL ARTICLE
LUNG CANCER
Introduction
Toxoplasma gondii is an intracellular protozoan parasite which can be found in all warm-blooded animals.
This parasite can only complete its full life cycle in cats, but nevertheless around 30% of the human
population, globally, is estimated to be infected [1–3]. Current estimates of human infection range from a
relatively lower prevalence in countries like the UK (10%), China (10%) and the USA (10–20%) [2, 4] to
areas where prevalence can exceed 40% (e.g. parts of continental Europe and South America) [2]. The
main routes of transmission to humans are thought to be via ingestion of infective oocysts shed by
infected cats or by ingestion of parasite cysts from undercooked meat. Congenital transmission, although
reported to be infrequent, contributes to transmission and is often associated with significant neonatal
pathology and possible miscarriage [5–8]. Other accidental routes of transmission have also been reported
(e.g. blood transfusion and organ transplantation). With the exception of congenital transmission, primary
infection in humans is usually asymptomatic in healthy individuals. If symptoms occur, they are usually
mild influenza-like symptoms, occasionally accompanied by hepatosplenomegaly and lymphadenopathy,
but are usually self-limiting [3, 9]. In immunosuppressed and immunodeficient patients T. gondii infection
can have fatal consequences [10]. T. gondii can invade every type of nucleated cell in the body, but
preferred target organs are the lymph nodes, brain, heart and lungs. Proliferation of tachyzoites results in
the infection of neighbouring cells and necrosis [11, 12]. Common presentations include encephalitis,
miscarriages, pneumonia and myocarditis [3].
Patients with cancer may have deficient cellular immunity that has allowed dysregulated proliferating cells to
escape immune defences, and are potentially susceptible to opportunistic infections including T. gondii [5].
Not much is known about toxoplasmosis in this group of patients and few reports are available. As
examples of studies of T. gondii infection in cancer patients [13], serological measurement of infection
rates showed high prevalences in nasopharyngeal carcinoma (46.2%) and rectal cancer (63.6%), but lower
rates in the other cancer groups, for example, pulmonary carcinoma (4.6%), breast cancer (9.5%), gastric
carcinoma (10.0%), hepatocellular carcinoma (14.3%) and uterine cervix carcinoma (12.5%). This might
suggest that there is an association between T. gondii infection and some types of cancer; however, these
studies give little indication as to whether active infection is present, and they measure generic infection
status rather than localised infection status in the cancer affected tissue. The objectives of this study were
to use specific DNA based and immunohistochemical detection systems to detect the presence of the
parasite, T. gondii, in lung biopsy samples taken from a well-characterised collection of patients with lung
cancer. A secondary aim was to investigate any associations between parasite infection intensity or active/
dormant infection and other recorded characteristics of these lung cancer patients (such as sex, age,
presence of chronic obstructive pulmonary disease (COPD) and smoking history).
Materials and methods
Study subjects and sample processing
In total, 72 tissue samples were collected from patients undergoing lung resection surgery at University
Hospital of South Manchester as part of their clinical care in the National Health Service (NHS). These
patients were not specifically recruited for this study but were referred to the hospital with suspected lung
cancer and biopsies were taken as part of the diagnostic process. This centre serves a large catchment area
covering referrals for lung diseases across the north-west of England. The samples were taken for
exploratory investigations as part of suspected lung cancer diagnosis and were taken prior to any
anti-cancer drug therapy. All 72 patients were subsequently confirmed as having lung cancer following all
subsequent diagnostic tests. Routine diagnosis for cancer does not involve serological testing for
Toxoplasma infection, thus none of these patients were tested in this way. To act as controls, a further 10
bronchial biopsy samples were obtained from healthy subjects without any history or evidence of lung
cancer who were recruited specifically as healthy controls. The potential risk of biopsy to healthy subjects
made it difficult to gain a large sample size of control subjects. The control subjects were selected from the
same population catchment area as the lung cancer patients and covered a comparable age range, although
they have a lower average age (table 1). We recognise the limitations of the control sample, the relatively
small numbers, the younger average age range and different tissue type (bronchial rather than lung
biopsy), but it was not possible with this study to recruit more appropriate controls. These limitations are
discussed later in this article. The overall study methodology is presented in figure 1. The studies were
approved by the local South Manchester research ethics committee (03/SM/396, lung tissue collection) and
the NRES Committee North West – Greater Manchester South (06/Q1403/156, control sampling). All
subjects provided written informed consent. The study also received ethical approval from the University
of Salford Research Governance and Ethics (CST 12/37 and ST16/124). For each sample, data was
available on age, sex, lung conditions (e.g. COPD) if present, pack-years smoking history, and inhaled
medication use including bronchodilators and inhaled corticosteroids.
https://doi.org/10.1183/23120541.00143-2018 2
LUNG CANCER | J. BAJNOK ET AL.
Tissue sections were obtained from the lung as far distal to the tumour as possible, as determined by an
NHS pathologist. Lung tissue was washed in sterile PBS prior to use. A portion of the tissue was fixed with
10% formalin in PBS buffer and embedded in paraffin, using a Leica TP1020 automatic tissue processor
(Leica Microsystems (UK) Ltd, Milton Keynes, UK). Tissues were sectioned into 5 µm slices and lifted
TABLE 1 Summary of patient demographics
Males/
females
Age
years
FEV1 L FEV1 %pred FVC L FEV1/FVC
ratio
Smoking
history
pack-years
Lung
cancer
lesion
Recorded
medications
SAB LAB ICS
COPD, current smoker 10/6 70.9
(60–82)
1.9
(0.9–3.5)
74.6
(53–96)
3.3
(1.7–5.4)
59.0
(46–75)
56.9
(9–124)
Yes 7 4 4
COPD, ex-smoker 17/2 72.1
(60–80)
1.7
(1.3–2.5)
64.8
(45–118)
3.0
(2.4–4.5)
56.3
(42.5–69.3)
48.7
(11–112)
Yes 9 12 9
No airflow obstruction,
current smoker
4/13 64.4
(44–78)
2.3
(1.6–3.3)
105.2
(70–131)
3.1
(2.1–4.4)
73.1
(66.9–82.5)
44.2
(15–90)
Yes 0 0 0
No airflow obstruction,
ex-smoker
9/8 72.1
(57–84)
2.1
(1.2–3.2)
91.9
(47–127)
2.9
(1.8–4.1)
71.2
(55–85.8)
37.3
(2.1–117)
Yes 1 1 1
Never smoker 0/3 68.3
(65–71)
1.9
(1.8–2.0)
108.3
(100–113)
2.7
(2.2–3.6)
82.5
(77–91)
0 (0) Yes 1 0 1
Average for lung cancer
group
40/32
(total)
69.8
(44–84)
2.0
(0.87–3.5)
84.8
(45–131)
3.1
(1.69–5.4)
65.5
(42.5–90.9)
44.1
(0–124)
Yes 18 17 15
Healthy, never smoker
controls
7/3 52.2
(31–75)
3.3
(2.3–4.18)
107
(82.7–148.6)
4.3
(2.9–5.6)
78.6
(70.8–95.1)
0.0 (0) No 0 0 0
Subject demographics of cancer patients (n=72) and healthy nonsmoker control subjects (n=10). Data are presented as the mean (range) or
n. FEV1: forced expired volume in 1 s; FVC: forced vital capacity; SAB: short-acting bronchodilators; LAB: long-acting bronchodilators; ICS:
inhaled corticosteroid.
72 lung biopsy tissue samples were collected from patients, with suspected lung cancer, presenting for exploratory lung 
cancer diagnostic procedures. None of the patients had undergone anti-cancer drug therapy prior to exploration. All were 
shown to have confirmed cancer post-diagnosis. 10 control bronchial biopsy samples were collected from subjects 
without cancer. Serological testing for Toxoplasma infection was not carried out on the patients as this was not part of the 
diagnostic regime (retrospective Toxoplasma serological testing was not possible on these patients).
DNA samples
tested for
Toxoplasma
using specific
B1 gene
PCR 
(3 replicates)
Positive PCR amplification in all three replicates of a given Toxoplasma gene indicates 
presence of that DNA sequence in the DNA of the given lung cancer patient/control.
Positive amplification of all five independent markers is taken as confirmation that the 
patient is diagnosed positive for Toxoplasma DNA in the lung tissue sample control.
Positive staining with 
antibodies and visual
appearance confirms
presence of
Toxoplasma life cycle
stages in lung tissue of
the patient/control.
For patient biopsy samples and control biopsy samples, DNA was extracted for PCR and tissue sections were prepared for
1) IHC and 2) HE staining
Lung tissue/control samples positive for all PCR markers and by IHC, using specific 
antibodies, are considered infected. HE staining provides supportive evidence of 
positivity.
Identification of HE
stained structures 
showing possible 
Toxoplasma life cycle 
stages used to support 
IHC conclusions.
DNA samples
tested for
Toxoplasma
using specific
SAG1 gene
PCR 
(3 replicates)
DNA samples
tested for
Toxoplasma
using specific
SAG3 gene
PCR 
(3 replicates)
DNA samples
tested for
Toxoplasma
using specific
SAG2 gene 
3' end PCR 
(3 replicates)
DNA samples
tested for
Toxoplasma
using specific
SAG2 gene 
5' end PCR 
(3 replicates)
Tissue sections 
tested by IHC for 
Toxoplasma
using specific 
anti-Toxoplasma
specific 
antibodies
Tissue sections 
examined using 
HE staining for 
evidence of 
Toxoplasma-like 
structures
FIGURE 1 Flowchart showing the study methodology. IHC: immunohistochemistry; HE: haematoxylin and eosin.
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onto poly-L-lysine glass slides. Portions of tissue were snap frozen in liquid nitrogen, stored at −80°C and
used later for DNA extraction. Control bronchial biopsies were collected from subjects and immediately
fixed using 10% neutral buffered formalin (CellPath, Newtown, UK), processed and paraffin embedded.
4 µm sections were cut and lifted onto poly-L-lysine coated glass slides (Surgipath, Peterborough, UK).
PCR detection of T. gondii in human lung samples
DNA from 72 lung cancer patients and 10 control subjects was extracted from small blocks of snap frozen
tissue or directly from sections on poly-L-lysine microscope slides, using proteinase K lysis followed by
phenol/chloroform extraction as previously described [14]. Extracted DNA was tested using a mammalian
α-tubulin PCR to ensure the viability of the DNA for PCR amplification [15]. Protocols and processes
were applied to prevent cross contamination of PCR reactions as previously described [16–19]. The
presence of the parasite was tested with five markers at four genetic loci: SAG1, SAG2 (the 3′ and 5′ ends
were tested separately), SAG3 and B1 [20–22] as previously described [19]. All of these markers are
commonly used specific PCR diagnostic markers for T. gondii. Pure parasite DNA from the T. gondii RH
strain and from a type II strain, isolated from a goat in Slovakia [19] were used as positive controls.
Negative controls (water) were interspersed throughout the PCR reactions to detect any possible false
amplification and DNA extraction controls from sham blocks were also included as negative controls. Any
experiment in which the negative controls showed amplification was discarded and repeated. PCR
amplifications were conducted in replicates; each sample was tested three times. PCR products were
visualised by agarose gel electrophoresis using standard methods and were sequenced to confirm that the
correct amplicons were amplified. The DNA samples were considered to be positive for T. gondii if they
successfully amplified in all three reactions with all five Toxoplasma specific markers.
Immunohistochemical detection of T. gondii in human lung sections
Using established approaches [23], immunohistochemistry (IHC) was performed on paraffin embedded
tissue using commercial anti-T. gondii polyclonal antibodies produced in rabbits (Thermo Fisher Scientific,
Catalogue number PA1-38789, Rockford, IL, USA). This antibody was generated from a whole Toxoplasma
gondii lysate, has been validated for IHC (Thermo Fisher) and used in previous studies (e.g. [24]).
The 5 µm tissue sections were cut and mounted on positively charged glass slides then dewaxed in
Histoclear (2×5 min), rehydrated in alcohols (ethanol), 100% (5 min), 90% (3 min), 75% (2 min) and 50%
(1 min). They were finally rinsed in tap water to remove the ethanol for 5 min. Antigen retrieval was
performed in 1% trypsin/calcium chloride (pH 7.8) at 37°C for 30 min in a humidified chamber [25].
After incubation, the sections were left to cool at room temperature for 10 min, then washed in PBS
Tween 20 twice for 2 min. Endogenous peroxidase activity was blocked by incubating slides in 0.3%
hydrogen peroxide for 30 min at room temperature followed by washing in TBS. Nonspecific antibody
binding was blocked using normal goat serum (Vectastain ABC Systems, Vector Laboratories,
Peterborough, UK) for 30 min at room temperature and followed by incubation in diluted (1/100)
polyclonal rabbit anti-T. gondii antibodies for 1 h at room temperature. Following this incubation, the
slides were washed in TBS Tween for 3×3 min and incubated in biotinylated goat anti-rabbit secondary
antibody (Vectastain ABC Systems) for 30 min at room temperature followed by another wash in TBS
Tween (3×3 min). Slides were incubated in ABC-Px mix (Vectastain ABC Systems) for 30 min, and
re-washed ×3 in TBS. The resulting complex was visualised using 3-3′-diaminobenzidine (DAB) for a
maximum of 10 min. The intensity of the tissue staining was monitored using light microscopy and the
DAB reaction quenched in distilled water when optimal staining was reached. Sections were then washed
with running water for 5 min, counterstained with haematoxylin for 45 s, washed with water for another
5 min, dehydrated with alcohols, 50% (1 min), 75% (2 min), 95% (4 min), and 100% (5 min), cleared in
Histoclear (2×5 min) and mounted, using cover slips, in DPX. Three negative controls were used for each
staining. These were lung sections from T. gondii negative wood mouse (Apodemus sylvaticus), human
lung sections with primary antibodies omitted and cells derived from a C2C12 culture (mouse myoblast
cell line, free of T. gondii) with both primary antibodies present and absent. Specific T. gondii staining was
not observed in any negative controls. Cell culture derived T. gondii RH strain tachyzoites and lung tissue
from a T. gondii infected wood mouse were used as positive controls [19]. Specific T. gondii staining was
observed in all positive controls. Immunostained slides were also assessed using quantitative criteria. The
program ImageJ (https://imagej.nih.gov/ij/) was used to calculate a percentage score which described the
degree of coverage of infected tissue on each slide. For each patient, three microscope fields of view (×400
magnification) were randomly selected, photographed and quantified using ImageJ software (as a
percentage of stained pixels with respect to total pixels). The mean percentage of pixels in the stained
areas was calculated for each slide. According to the calculated mean (a measure of parasite intensity) the
patients were divided into three grades of staining. Grade 1 had a staining of <10% of the area covered,
grade 2 between 10 and 20% and grade 3 intensity of >20%. In addition to overall percentage cover, slides
were analysed in more detail and percentage coverage for different parasite life cycle stages were recorded
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(T. gondii cysts, intracellular infection of macrophages (or other cell types) and free tachyzoites). Finally,
haematoxylin and eosin (HE) staining was used to confirm that structures compatible with T. gondii stages
could be observed within sections [26].
Statistical analyses
To compare infection status of lung cancer patients (n=72) and non-lung cancer control patients (n=10),
2×2 contingency tables were used. Fisher’s exact test was used to calculate p-values and values of <0.05
were considered statistically significant. In order to investigate any relationships between T. gondii infection
and demographic data collected from within the lung cancer patient cohort (n=72), logistic regression
(generalised linear model with a binomial distribution) was used to avoid the statistical pitfalls of
conducting multiple univariate analyses. Model selection was based on backwards selection with only
those factors remaining significant at a level of p<0.05 being included in the final model. This approach
was used to avoid the pitfalls of confounding variables. As all lung cancer patients were infected, this
analysis used the following variables for parasite infection status: Toxoplasma infection intensity
(i.e. grades 1–3) and active/inactive parasite stages. Intensity grades were assessed by IHC staining using
Image J analysis of pixel coverage, as described above, and also included distinction between active
(presence of tachyzoites and infected cells) and inactive stages (presences of cysts alone). Dependent
variables used in the model for parasite infection were inactive versus active infection. Data on patient status
was also recorded as follows: sex, age, presence of COPD and smoking history. Lung cancer patients were
placed into two categories (dependent variables), “No COPD” subjects (no airflow obstruction as
determined by normal spirometry) or “COPD” subjects (Global Initiative for Chronic Obstructive Lung
Disease criteria), and considered against factors that predicted individuals in each category. Factors
considered included age, sex of the individual and a number of measures of smoking and Toxoplasma
infection intensity and active/inactive stage status. Patient-associated dependent variables were as follows:
smoker, “pack-year history” (1 pack-year is defined as 20 cigarettes per day for 1 year) and non-smoker;
current smoker versus non-smoker; prior medication versus non-medication. Only one patient- or
Toxoplasma-associated variable was considered at a time and all combinations were considered. Model
selection was based on backwards selection with only those factors remaining significant at a level of p<0.05
being included in the final model. All analyses were undertaken using R 3.01 (RCore Team, 2013) [27].
Results
DNA and tissue samples, for IHC, were collected from resected lung tissues from lung cancer patients
(n=72) and non-lung cancer healthy control subjects (n=10). Patient demographics are shown in table 1
and figure 1 illustrates the overall methodology used to examine the samples. Initially, DNA was extracted
successfully from tissue from all subjects. All samples were tested for the absence of PCR inhibition using
amplification of the mammalian α-tubulin gene. All samples showed successful PCR amplification of the
α-tubulin gene and were used for T. gondii DNA PCR detection using three replicated experiments of five
genetic markers at four independent loci: SAG1, SAG2 (3′ and 5′ ends), SAG3 and B1. Multiple
independent markers were used to rule out the possibility that individual markers could nonspecifically
amplify as can happen with Toxoplasma in single marker PCR or qPCR. All tested lung cancer patient
samples (32 females, 40 males) were found to be T. gondii positive, giving a prevalence of 100% with all
five genes. Of the 10 healthy control subjects, one sample showed positive amplification for all T. gondii
markers and the remaining nine did not amplify with any of the T. gondii specific primers. To confirm the
presence of the parasite, using an independent detection system, the tissue sections were examined by IHC
using specific anti-T. gondii antibodies. This was followed by secondary confirmation using HE staining.
IHC was performed on all tissue sections enabling both detection of the parasite and identification of the
life cycle stage. Infected tissue could be identified as containing T. gondii cysts, intracellular infection of
macrophages (or other cell types) and free tachyzoites (figure 2). All 72 lung cancer patient tissue samples
showed positive staining with the anti-T. gondii antibody and thus confirmed the PCR detection results of
100% (95% CI: 95.19–100%) prevalence in this cohort. Only one sample in the control group showed
specific staining with the anti-T. gondii antibody and this was the same sample that showed positive
amplification for the five T. gondii specific PCR amplifications. There was an extremely significant
difference in prevalence between the lung cancer group (n=72) and the non-cancer control group (n=10)
(p<0.0001, Fisher’s exact test). A surprisingly high proportion of lung cancer patients (95.8%; n=69)
showed evidence of an active form of infection, as defined by the presence of tachyzoites or infected
alveolar macrophages (or other cell types). Only three lung cancer subjects (4.2%) had the dormant cyst
stage as the only stage present. This is indicative of a latent infection in these three patients. Image J was
used to measure the proportion of infected cells and infected areas of the lung tissue. A quantitative score
was calculated for each type of life cycle stage individually and an overall score determined (see materials
and methods) for each lung tissue sample (table 2). Both T. gondii cysts and infected cells were observed
in the single infected non-cancer control sample. All samples were also stained with HE and observed
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a)
d)
f) g) h)
e)
b) c)
FIGURE 2 Anti-Toxoplasma gondii antigen immunostaining of human lung and control tissues. a) Cell culture
derived T. gondii RH strain tachyzoites stained with polyclonal anti-T. gondii antibodies. Brown staining
indicates detection of T. gondii. Positive control (×400 magnification, scale bar = 100 µm). b) Human lung
section stained with polyclonal anti-T. gondii antibodies with primary antibodies omitted. Negative control
(×400 magnification, scale bar = 100 µm). c) Cells derived from a C2C12 culture (mouse myoblast cell line)
which is T. gondii free and stained with polyclonal anti-T. gondii antibodies. Negative control (×400
magnification, scale bar = 100 µm). d) Lung tissue from a T. gondii infected wood mouse (Apodemus sylvaticus)
stained with polyclonal anti-T. gondii antibodies. Brown staining indicates detection of T. gondii. Positive
control (×400 magnification, scale bar = 100 µm). e) Human lung section, from subject 1045, stained with
polyclonal anti-T. gondii antibodies. T. gondii cysts can be seen (examples indicated with white arrows) (×400
magnification, scale bar = 100 µm). f ) Human lung section, from subject 1040, stained with polyclonal
anti-T. gondii antibodies. Alveolar macrophages infected with T. gondii can be seen (×400 magnification, scale
bar = 100 µm). g) Human lung section, from subject 1028, stained with polyclonal anti-T. gondii antibodies. By
observation of cell morphology, fibroblasts infected with T. gondii can be seen (examples indicated with white
arrows) (×400 magnification, scale bar = 100 µm). h) Human lung section, from subject 975, stained with
polyclonal anti-T. gondii antibodies. Ruptured T. gondii cysts and free T. gondii tachyzoites can be seen
(×400 magnification, scale bar = 100 µm).
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under the light microscope. Although less specific as a diagnostic technique than the IHC and PCR, the
presence of structures consistent with infection by the parasite was confirmed in 67 out of 72 tissue
sections from the lung cancer patients and in one out of 10 of the non-cancer control group. In the latter
case, this corresponded to the sample that was positive for the PCR amplifications and IHC. The
remaining lung cancer samples could not be reliably confirmed as potentially infected by this method, but
could have possessed less visible structures such as tachyzoites. Using the HE staining technique, infected
cells, macrophages and some tissue cysts were observed (figure 3) but no free tachyzoites could be
detected.
By quantifying the Toxoplasma infection intensity among the 72 lung cancer patients, we were able to
evaluate any relationship between parasitic load and presence of COPD or other demographic factors. Our
cohort did not show any significant association between Toxoplasma infection load with patient smoking
history (both total exposure (p>0.05) or current exposure (p>0.05)) or airflow obstruction in COPD
(p>0.05). All other analyses conducted had non-significant p-values (p>0.05) except for a parasitologically
unrelated association between COPD and sex (males>females; p<0.05).
Discussion
In this study, we investigated the prevalence of T. gondii in clinical samples from patients with lung cancer
using PCR and T. gondii specific IHC. Surprisingly, of the 72 subjects admitted to hospital for examination
for lung cancer, all (100%) showed evidence of infection of lung tissue by the parasite T. gondii. A
significant difference was observed between the prevalence in these lung cancer patients and in a
non-cancer control group. Of the lung cancer patients, 95.8% showed evidence of active infection as
opposed to being in the dormant (cyst) stage. Four stages of infection were observed by IHC: cysts,
infected macrophages, other cell types infected and free-living tachyzoites. Given that the background
levels of infection in the UK are considered to be low at 10% and the global infection rate is 30% [2], this
represents an extremely high infection rate in these cancer patients. While detailed prevalence figures have
not recently been determined for the catchment area sampled, it is unlikely that it significantly deviates
TABLE 2 Life cycle stages of Toxoplasma gondii and type of infection in lung cancer patients
(n=72) as identified by immunohistochemistry
Infection type Subjects n Range of percentage score# Infection status
Cysts 3 0.2–2.9% Inactive
Tachyzoites 3 0.8–8.7% Active
Macrophages or other cells 18 0.6–34.2% Active
Mixture 48 1.1–44.0% Active
Total infections 72
#: the score was determined as described in the materials and methods.
b) c)a)
FIGURE 3 Haematoxylin and eosin staining of human lung sections. a) Infected alveolar macrophage with four
visible tachyzoites (red arrow) in subject 1040 (×400 magnification, scale bar = 10 µm). b) Tissue cyst from
subject 1070 (×400 magnification, scale bar = 10 µm) and (c) young tissue cyst in subject 1028 (×400
magnification, scale bar = 10 µm).
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from the national average. The most recent studies in the UK show infection in a range of 7–34% [2,
28–30]. In our study, we were able to evaluate Toxoplasma infection in 10 samples from healthy subjects
without cancer who were specifically recruited as controls and were similarly age range matched with the
cancer patients (although with a lower average age). We acknowledge some limitations in the control
group; however, it was difficult to achieve a suitably sized and matched control group due to the potential
risks of lung biopsy techniques. For example, one limitation was the comparison of lung tissue versus
bronchial tissue. However, as T. gondii can infect any nucleated cell types and that both tissue types will
have the same exposure to parasite infection, we consider minimal impact of these limitations on the
conclusions. We also acknowledge potential bias due to the relatively small control sample size and
younger average age of the control population, which is again related to the difficulty and risks associated
with sampling healthy subjects. However, taken alongside the many studies of prevalence in the UK [2,
28–30], this study has demonstrated an unexpectedly high prevalence of Toxoplasma infection in lung
cancer patients compared with control subjects and with the expected UK prevalence in people without
cancer.
Toxoplasmosis has been reported to increase the fatality rate in a variety of cancers such as Hodgkin’s
disease, leukaemia, melanoma and brain cancer [31–35]. However, Toxoplasma infection causing
complications in lung cancer has been reported only rarely. A case report demonstrated that a T. gondii
infection was detected in a patient with lung cancer [36]. The diagnosis was based on tachyzoites present
in bronchoalveolar lavage and detection of specific IgM antibodies. Most of the studies that investigate the
link between cancer and T. gondii infection are based on serological prevalence detection of the parasite in
cohorts of cancer patients rather than by direct investigation of tissue samples. Overall 8.38% of examined
patients with malignant neoplasms in China were seropositive for antibodies against T. gondii. However,
when nested PCR detection was used on the same samples, only 3.55% of these patients were positive [37].
In another study from China [38], much higher prevalence was detected, with 35.56% of the cancer
patients overall being positive for anti-T. gondii IgG. The highest prevalence of infection, in this study [38],
was observed in lung cancer patients (60.94%) followed by cervical cancer patients (50%). Among 356
cancer patients, 21 (5.9%) cases were found to be IgG-positive and 8 (2.3%) were IgM-positive, and five of
them were found to have both IgG and IgM antibodies [39]. The total seroprevalence of Toxoplasma
infection in this study was 6.8% [39]. A study in Iran concluded that 45.2% of cancer patients were
seropositive for T. gondii [40]. High seropositivity rates were detected in women with breast cancer
(86.4%) [41]. In a study comparing national figures from 37 countries [42], it was found that brain
cancers are 1.8 times more common in countries where T. gondii infections are more prevalent than in
those where it is virtually absent. Overall, the studies that investigate cancer and T. gondii infection
generally show no particular link, although these studies are rarely specifically addressing the link or are
controlled against a healthy cohort. As far as we can determine, our study is the first that specifically
investigates the link between cancer affected lung tissue and T. gondii. Unfortunately, while we recognise
the value of it, we were not able to investigate the seropositivity of our cohort of cancer patients since
there is no formal process of Toxoplasma testing as part of lung cancer diagnostic protocols. Subsequent
follow-up is not possible due to some subjects having passed away since diagnosis and the length of time
since diagnosis could complicate the serological outcomes. Our study suggests that routine serological
testing for Toxoplasma may be of value in lung cancer diagnostic protocols.
Using additional data associated with our sample set, the relationship between patient health and T. gondii
infection was investigated to see if there were any further factors associating with patient health. We
investigated which factors were associated with predicting whether an individual had normal lung function
(no COPD) or “patients” (COPD) using logistic regression. This multiple regression analysis takes into
account that the data are not normally distributed and follows a binomial distribution. We investigated the
effects of age and sex, as well as a range of different smoking parameters (smoker, non-smoker and
pack-year smoking history) and Toxoplasma infection measures (Toxoplasma intensity of infection,
presence of free tachyzoites, acute or active infection). We only looked at one smoking and one infection
related measure at a time, but considered all possible combinations (e.g. smoker and parasite intensity,
then smoker and free tachyzoites, then smoker and acute infection) and each factor on its own (e.g.
smoker). The final model we selected included only sex as a factor and we showed that males were more
likely to have an obstruction than females in our cohort. There was no significant effect of smoking or
stage/extent of Toxoplasma infection on the likelihood of being a lung “patient” (i.e. having COPD) in this
sample set. While the sex relationship is clearly of interest in relation to lung disease, it does not have
relevance to the T. gondii infection reported here. COPD has been linked to a higher risk in the male
population, until more recently when it is now predicted that incidence in females will overtake that of
males as a possible result of an increased proportion of female smokers in Western societies [43]. We
recognise that there are limitations in our regression analyses and there were many potentially
confounding parameters where no data were available. For example, most studies on T. gondii infection
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include risk factors for infection. As no previous studies on lung cancer patients have revealed such
striking prevalence levels as this study, there has been little reason to investigate parasitological parameters.
In the future, detailed studies are required which involve more specific questions pertinent to the results
presented here.
The high frequency of T. gondii infection in these lung cancer patients raises questions about whether the
two conditions are linked. It is unlikely that there is a direct cause and effect linkage as there are no
reported causative effects of T. gondii infection on producing cancers, as far as we are aware. However,
many types of cancer can cause immunomodulatory effects on affected tissues and individuals [44] and
Toxoplasma infection may also provoke a state of immunosuppression by affecting thymic related T-cell
activity as systemic Toxoplasma infection triggers a long-term defect in the generation and function of
naïve T-lymphocytes [5, 45–48]. Furthermore, pulmonary toxoplasmosis is generally considered to be rare
in immunocompetent hosts [49], further supporting the idea that these patients are immunocompromised
(at least locally within the lung tissue). Based on the observations reported in this article, a high
proportion of lung cancer patients potentially could be at risk of acute infection or reactivation of chronic
infection from T. gondii. This could lead to complications such as pulmonary toxoplasmosis, a serious
condition causing a high mortality rate, which could seriously affect general wellbeing and interfere with
treatment. Further research is required to establish the wider significance of these findings but in the
meantime, we suggest that all lung cancer patients (and possibly patients with other cancers) should be
considered at risk of T. gondii infection and, if necessary, monitored to prevent further complications
during their treatments.
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